As the prodromal and preclinical stages of Alzheimer’s disease (AD) become targets for disease-modifying agents, it is important to be able to identify candidates for clinical trials that are in these stages. Pre-screening participants using biomarkers can help to achieve this. João Pedro Ferrari-Souza, MD-PhD student, University of Pittsburgh, Pittsburgh, PA, explains the potential of using plasma phosphorylated tau181 (p-tau181) and neurofilament light (NfL) for AD therapeutic trial pre-screening. These biomarkers could reduce the cost of AD clinical trials by reducing the required sample size. However, a recent study has shown that using p-tau181 or NfL as surrogate markers was not cost effective, compared to using standard neuroimaging outcomes. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
